Clinical use of biomarkers of survival in pulmonary fibrosis

Respir Res. 2010 Jun 28;11(1):89. doi: 10.1186/1465-9921-11-89.


Background: Biologic predictors or biomarkers of survival in pulmonary fibrosis with a worse prognosis, more specifically in idiopathic pulmonary fibrosis would help the clinician in deciding whether or not to treat since treatment carries a potential risk for adverse events. These decisions are made easier if accurate and objective measurements of the patients' clinical status can predict the risk of progression to death.

Method: A literature review is given on different biomarkers of survival in interstitial lung disease, mainly in IPF, since this disease has the worst prognosis.

Conclusion: Serum biomarkers, and markers measured by medical imaging as HRCT, pertechnegas, DTPA en FDG-PET are not ready for clinical use to predict mortality in different forms of ILD. A baseline FVC, a change of FVC of more than 10%, and change in 6MWD are clinically helpful predictors of survival.

Publication types

  • Review

MeSH terms

  • Biomarkers / blood
  • Diagnostic Imaging / methods
  • Exercise Test
  • Humans
  • Predictive Value of Tests
  • Prognosis
  • Pulmonary Fibrosis / blood
  • Pulmonary Fibrosis / diagnosis
  • Pulmonary Fibrosis / mortality*
  • Pulmonary Fibrosis / physiopathology
  • Respiratory Function Tests
  • Risk Assessment
  • Risk Factors
  • Survival Analysis
  • Time Factors


  • Biomarkers